Next generation antibody drugs: pursuit of the 'high-hanging fruit'

Screening-based approaches to identify small molecules that inhibit protein–protein interactions

(2017) Sehee Choi et al.   Expert Opinion on Drug Discovery

PEGylation prolongs the pulmonary retention of an anti-IL-17A Fab’ antibody fragment after pulmonary delivery in three different species

(2017) Danielle Freches et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells

(2017) Annalina Tammen et al.   JOURNAL OF IMMUNOLOGY

The making of bispecific antibodies

(2017) Ulrich Brinkmann et al.   mAbs

Chaperone proteins as single component reagents to assess antibody nonspecificity

(2017) Ryan L. Kelly et al.   mAbs

Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates

(2017) Miroslav Dostalek et al.   mAbs

Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs

(2017) Julian Andreev et al.   MOLECULAR CANCER THERAPEUTICS

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

(2017) Frederick L. Locke et al.   MOLECULAR THERAPY

Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies

(2017) Elie Dheilly et al.   MOLECULAR THERAPY

Stop Alzheimer’s before it starts

(2017) Eric McDade et al.   NATURE

Therapeutic T cell engineering

(2017) Michel Sadelain et al.   NATURE

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

Industry 'road tests' new wave of immune checkpoints

(2017) Ken Garber   NATURE BIOTECHNOLOGY

Opportunities for therapeutic antibodies directed at G-protein-coupled receptors

(2017) Catherine J. Hutchings et al.   NATURE REVIEWS DRUG DISCOVERY

Strategies and challenges for the next generation of antibody–drug conjugates

(2017) Alain Beck et al.   NATURE REVIEWS DRUG DISCOVERY

Antibody therapies in CNS diseases

(2017) Per-Ola Freskgård et al.   NEUROPHARMACOLOGY

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antidrug Antibodies in Patients Treated with Alirocumab

(2017) Eli M. Roth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

(2017) Johannes Oldenburg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nanobodies® † †Nanobody is a registered trademark of Ablynx NV. as inhaled biotherapeutics for lung diseases

(2017) Gino Van Heeke et al.   PHARMACOLOGY & THERAPEUTICS

Biophysical properties of the clinical-stage antibody landscape

(2017) Tushar Jain et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pharmacokinetic aspects of retinal drug delivery

(2017) Eva M. del Amo et al.   PROGRESS IN RETINAL AND EYE RESEARCH

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Long-acting protein drugs for the treatment of ocular diseases

(2017) Joy G. Ghosh et al.   Nature Communications

Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration

(2017) Seung-Min Shin et al.   Nature Communications

Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence

(2017) Yariv Mazor et al.   Scientific Reports

A quantitative comparison of cytosolic delivery via different protein uptake systems

(2017) Wouter P. R. Verdurmen et al.   Scientific Reports

Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases

(2017) Taku Fukuzawa et al.   Scientific Reports

Oral delivery of macromolecular drugs: Where we are after almost 100 years of attempts

(2016) Elena Moroz et al.   ADVANCED DRUG DELIVERY REVIEWS

Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody-Drug Conjugates

(2016) Matthew R. Levengood et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Antibody drug conjugates: lessons from 20 years of clinical experience

(2016) A. W. Tolcher   ANNALS OF ONCOLOGY

Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence

(2016) Ira Jacobs et al.   BIODRUGS

Assessing the Immunogenicity of Biopharmaceuticals

(2016) Carlos Pineda et al.   BIODRUGS

Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement

(2016) Rony Dahan et al.   CANCER CELL

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

(2016) John Y. Li et al.   CANCER CELL

4-1BB agonism: adding the accelerator to cancer immunotherapy

(2016) Cariad Chester et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects

(2016) Saswata Talukdar et al.   Cell Metabolism

Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection

(2016) Eugene A Zhukovsky et al.   CURRENT OPINION IN IMMUNOLOGY

Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease

(2016) Davide Corti et al.   CURRENT OPINION IN IMMUNOLOGY

Immunocytokines for cancer treatment: past, present and future

(2016) Dario Neri et al.   CURRENT OPINION IN IMMUNOLOGY

Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?

(2016) Janine Schuurman et al.   CURRENT OPINION IN IMMUNOLOGY

Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions

(2016) Franziska Bootz et al.   DRUG DISCOVERY TODAY

The amyloid hypothesis of Alzheimer's disease at 25 years

(2016) Dennis J Selkoe et al.   EMBO Molecular Medicine

Rationale for anti-OX40 cancer immunotherapy

(2016) Sandrine Aspeslagh et al.   EUROPEAN JOURNAL OF CANCER

Re-engineering therapeutic antibodies for Alzheimer’s disease as blood-brain barrier penetrating bi-specific antibodies

(2016) William M. Pardridge   EXPERT OPINION ON BIOLOGICAL THERAPY

Opportunities and challenges for TCR mimic antibodies in cancer therapy

(2016) Aaron Y. Chang et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches

(2016) Vibhuti Agrahari et al.   Expert Opinion on Drug Delivery

CSF, blood-brain barrier, and brain drug delivery

(2016) William M. Pardridge   Expert Opinion on Drug Delivery

Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody

(2016) Di Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial

(2016) M. Scott Harris et al.   Journal of Crohns & Colitis

Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions

(2016) Erika M. Cook et al.   JOURNAL OF IMMUNOLOGY

Antibodies to watch in 2017

(2016) Janice M. Reichert   mAbs

Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody

(2016) Songmao Zheng et al.   mAbs

Target-independent variable region mediated effects on antibody clearance can be FcRn independent

(2016) Ryan L. Kelly et al.   mAbs

Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys

(2016) Amita Datta-Mannan et al.   mAbs

The use of CrossMAb technology for the generation of bi- and multispecific antibodies

(2016) Christian Klein et al.   mAbs

Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63

(2016) B. E. C. G. de Goeij et al.   MOLECULAR CANCER THERAPEUTICS

Contribution of Antibody Hydrodynamic Size to Vitreal Clearance Revealed through Rabbit Studies Using a Species-Matched Fab

(2016) Whitney Shatz et al.   MOLECULAR PHARMACEUTICS

Failed Alzheimer’s trial does not kill leading theory of disease

(2016) Alison Abbott et al.   NATURE

In vitro and ex vivo strategies for intracellular delivery

(2016) Martin P. Stewart et al.   NATURE

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

A comprehensive map of molecular drug targets

(2016) Rita Santos et al.   NATURE REVIEWS DRUG DISCOVERY

Ten years of anti-vascular endothelial growth factor therapy

(2016) Napoleone Ferrara et al.   NATURE REVIEWS DRUG DISCOVERY

Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies

(2016) Y. Joy Yu Zuchero et al.   NEURON

A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses

(2016) Anna Z. Wec et al.   SCIENCE

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations

(2016) Sabrina Arena et al.   Science Translational Medicine

Coming-of-Age of Antibodies in Cancer Therapeutics

(2016) B. Vijayalakshmi Ayyar et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Cost-Effectiveness and Clinical Practice Guidelines: Have We Reached a Tipping Point?—An Overview

(2016) Louis P. Garrison   VALUE IN HEALTH

Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins

(2016) Alison Smith et al.   Journal of Immunology Research

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

(2015) Laurent Detalle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1

(2015) Takuya Osada et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy

(2015) A. V. Yurkovetskiy et al.   CANCER RESEARCH

Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect

(2015) David J. DiLillo et al.   CELL

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Principles of antibody-mediated TNF receptor activation

(2015) H Wajant   CELL DEATH AND DIFFERENTIATION

Antibody therapies and their challenges in the treatment of age-related macular degeneration

(2015) Cornelia Volz et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Oligoclonal antibodies to target the ErbB family

(2015) Jimson W D’Souza et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Structural analysis of Fc/FcγR complexes: a blueprint for antibody design

(2015) Jose M. M. Caaveiro et al.   IMMUNOLOGICAL REVIEWS

Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics

(2015) Daniela Bumbaca Yadav et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions

(2015) Avi Ashkenazi   JOURNAL OF CLINICAL INVESTIGATION

Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial

(2015) Michele Maio et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficient cell-specific uptake of binding proteins into the cytoplasm through engineered modular transport systems

(2015) Wouter P.R. Verdurmen et al.   JOURNAL OF CONTROLLED RELEASE

The Current Status and Prospects of Antibody Engineering for Therapeutic Use: Focus on Glycoengineering Technology

(2015) Rinpei Niwa et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Developability Assessment During the Selection of Novel Therapeutic Antibodies

(2015) Alexander Jarasch et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

An Immunosuppressive Antibody–Drug Conjugate

(2015) Rongsheng E. Wang et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism

(2015) C Krupka et al.   LEUKEMIA

Cross-reactive and pre-existing antibodies to therapeutic antibodies—Effects on treatment and immunogenicity

(2015) Karin A van Schie et al.   mAbs

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+tumor cells

(2015) Uwe Reusch et al.   mAbs

Improving target cell specificity using a novel monovalent bispecific IgG design

(2015) Yariv Mazor et al.   mAbs

Insights into the molecular basis of a bispecific antibody's target selectivity

(2015) Yariv Mazor et al.   mAbs

A novel screening method to assess developability of antibody-like molecules

(2015) Neeraj Kohli et al.   mAbs

A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells

(2015) Emily C Piccione et al.   mAbs

The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies

(2015) Amita Datta-Mannan et al.   mAbs

Aggregation risk prediction for antibodies and its application to biotherapeutic development

(2015) Olga Obrezanova et al.   mAbs

Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics

(2015) Amita Datta-Mannan et al.   mAbs

A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life

(2015) Colby A Souders et al.   mAbs

Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic

(2015) J. D. Kearns et al.   MOLECULAR CANCER THERAPEUTICS

Mechanisms of action of therapeutic antibodies for cancer

(2015) J.M. Redman et al.   MOLECULAR IMMUNOLOGY

Targeting FcRn for the modulation of antibody dynamics

(2015) E. Sally Ward et al.   MOLECULAR IMMUNOLOGY

ImmTACs for targeted cancer therapy: Why, what, how, and which

(2015) Joanne Oates et al.   MOLECULAR IMMUNOLOGY

Alternative molecular formats and therapeutic applications for bispecific antibodies

(2015) Christoph Spiess et al.   MOLECULAR IMMUNOLOGY

Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: Selective targeting to diseased versus healthy tissue

(2015) Susan Hua et al.   Nanomedicine-Nanotechnology Biology and Medicine

Novel antibody–antibiotic conjugate eliminates intracellular S. aureus

(2015) Sophie M. Lehar et al.   NATURE

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

(2015) Robert P Lyon et al.   NATURE BIOTECHNOLOGY

Monoclonal antibody biosimilars

(2015) Natasha Udpa et al.   NATURE REVIEWS DRUG DISCOVERY

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

(2015) Sandra M. Swain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival and digestibility of orally-administered immunoglobulin preparations containing IgG through the gastrointestinal tract in humans

(2015) Victoria S Jasion et al.   Nutrition Journal

Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics

(2015) Angela Schoch et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy

(2015) Jiemin Wu et al.   PROTEIN ENGINEERING DESIGN & SELECTION

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies

(2015) Liping L. Sun et al.   Science Translational Medicine

A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates

(2015) Gurunadh R. Chichili et al.   Science Translational Medicine

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer

(2015) R. Dienstmann et al.   Cancer Discovery

TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2

(2015) Taro Tamada et al.   Scientific Reports

A review of blinatumomab, a novel immunotherapy

(2015) Matthew J Newman et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab

(2015) Venky Ramakrishna et al.   Journal for ImmunoTherapy of Cancer

Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex

(2015) Ganesh Kolumam et al.   EBioMedicine

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity

(2015) Todd Bartkowiak et al.   Frontiers in Oncology

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal

(2015) Stefanie N. Linch et al.   Frontiers in Oncology

Safety and Pharmacokinetics of XOMA 3AB, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin A

(2014) S. U. Nayak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

pH-dependent antigen-binding antibodies as a novel therapeutic modality

(2014) T. Igawa et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL

(2014) J. A. Woyach et al.   BLOOD

Delivery of Antibody Mimics into Mammalian Cells via Anthrax Toxin Protective Antigen

(2014) Xiaoli Liao et al.   CHEMBIOCHEM

LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth

(2014) L. Liu et al.   CLINICAL CANCER RESEARCH

pH-dependent Binding Engineering Reveals an FcRn Affinity Threshold That Governs IgG Recycling

(2014) M. Jack Borrok et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Ocular delivery of macromolecules

(2014) Yoo Chun Kim et al.   JOURNAL OF CONTROLLED RELEASE

PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract

(2014) Salome Juliette Koussoroplis et al.   JOURNAL OF CONTROLLED RELEASE

Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system

(2014) L. Guilleminault et al.   JOURNAL OF CONTROLLED RELEASE

Fcγ Receptor Dependency of Agonistic CD40 Antibody in Lymphoma Therapy Can Be Overcome through Antibody Multimerization

(2014) Ann L. White et al.   JOURNAL OF IMMUNOLOGY

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

(2014) Ian E Krop et al.   LANCET ONCOLOGY

Non–antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity

(2014) Zenjiro Sampei et al.   mAbs

Non-viral adeno-associated virus-based platform for stable expression of antibody combination therapeutics

(2014) Gwendolyn M Wilmes et al.   mAbs

VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations

(2014) Virginie Hervé et al.   mAbs

Resolving self-association of a therapeutic antibody by formulation optimization and molecular approaches

(2014) Paul Casaz et al.   mAbs

Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19

(2014) Dániel Szili et al.   mAbs

A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells

(2014) Dong-Ki Choi et al.   mAbs

Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection

(2014) Alexandra Lavoisier et al.   mAbs

Highly Viscous Antibody Solutions Are a Consequence of Network Formation Caused by Domain–Domain Electrostatic Complementarities: Insights from Coarse-Grained Simulations

(2014) Patrick M. Buck et al.   MOLECULAR PHARMACEUTICS

A draft map of the human proteome

(2014) Min-Sik Kim et al.   NATURE

Biopharmaceutical benchmarks 2014

(2014) Gary Walsh   NATURE BIOTECHNOLOGY

Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle

(2014) Jens Niewoehner et al.   NEURON

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Complement Is Activated by IgG Hexamers Assembled at the Cell Surface

(2014) C. A. Diebolder et al.   SCIENCE

Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates

(2014) Y. J. Yu et al.   Science Translational Medicine

The global prevalence of dementia: A systematic review and metaanalysis

(2013) Martin Prince et al.   Alzheimers & Dementia

Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials

(2013) Alexander C Ford et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

(2013) Jedd D. Wolchok et al.   Annals of the New York Academy of Sciences

A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults

(2013) Gabriel J. Robbie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

(2013) S. H. Petersdorf et al.   BLOOD

The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes

(2013) Gregory Gaich et al.   Cell Metabolism

Agonistic CD40 Antibodies and Cancer Therapy

(2013) R. H. Vonderheide et al.   CLINICAL CANCER RESEARCH

Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics

(2013) Timo Rath et al.   CRITICAL REVIEWS IN BIOTECHNOLOGY

Targeting T cells to tumor cells using bispecific antibodies

(2013) Stanley R Frankel et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Viscosity of high concentration protein formulations of monoclonal antibodies of the IgG1 and IgG4 subclass – Prediction of viscosity through protein–protein interaction measurements

(2013) Martin S. Neergaard et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey

(2013) Chee M. Ng et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Evolutionary Survey of Druggable Protein Targets with Respect to Their Subcellular Localizations

(2013) Xiaotong Wang et al.   Genome Biology and Evolution

AVX-470

(2013) Kailash C. Bhol et al.   INFLAMMATORY BOWEL DISEASES

Inhaled proteins: Challenges and perspectives

(2013) Flore Depreter et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Asymmetrical Fc Engineering Greatly Enhances Antibody-dependent Cellular Cytotoxicity (ADCC) Effector Function and Stability of the Modified Antibodies

(2013) Zhi Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies

(2013) Jeong M. Kim et al.   JOURNAL OF EXPERIMENTAL MEDICINE

T Cell Costimulation with Anti-CD137 Monoclonal Antibodies Is Mediated by K63-Polyubiquitin-Dependent Signals from Endosomes

(2013) I. Martinez-Forero et al.   JOURNAL OF IMMUNOLOGY

The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients

(2013) C Kellner et al.   LEUKEMIA

Developability studies before initiation of process development

(2013) Xiaoyu Yang et al.   mAbs

Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant

(2013) Futa Mimoto et al.   mAbs

Antibody biodistribution coefficients

(2013) Dhaval K. Shah et al.   mAbs

Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics

(2013) Josée Golay et al.   mAbs

Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies

(2013) Gabriele Proetzel et al.   METHODS

Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity

(2013) Zenjiro Sampei et al.   PLoS One

Antibody-Mediated Activation of FGFR1 Induces FGF23 Production and Hypophosphatemia

(2013) Ai-Luen Wu et al.   PLoS One

Antitumor activities of agonistic anti-TNFR antibodies require differential Fc RIIB coengagement in vivo

(2013) F. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

(2013) M. Merchant et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool

(2013) Y. Xu et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Engineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131

(2013) F. Mimoto et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier

(2013) J. A. Couch et al.   Science Translational Medicine

Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index

(2013) L. R. Desnoyers et al.   Science Translational Medicine

Structural Basis for Enhanced HIV-1 Neutralization by a Dimeric Immunoglobulin G Form of the Glycan-Recognizing Antibody 2G12

(2013) Yunji Wu et al.   Cell Reports

Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti-CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fcγ Receptor IIb Inhibitory Receptor

(2013) Seung Y. Chu et al.   Arthritis & Rheumatology

Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer

(2013) L. P. Richman et al.   Cancer Immunology Research

Nebulized Anti–IL-13 Monoclonal Antibody Fab′ Fragment Reduces Allergen-Induced Asthma

(2012) Jonathan Hacha et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency

(2012) M Chodorge et al.   CELL DEATH AND DIFFERENTIATION

Dornase alfa (Pulmozyme)

(2012) Jeffrey S. Wagener et al.   CURRENT OPINION IN PULMONARY MEDICINE

Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody

(2012) Seung Y. Chu et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Increasing Serum Half-life and Extending Cholesterol Loweringin Vivoby Engineering Antibody with pH-sensitive Binding to PCSK9

(2012) Javier Chaparro-Riggers et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

(2012) Sylvie Castaigne et al.   LANCET

Marketing approval of mogamulizumab

(2012) Alain Beck et al.   mAbs

A strategy for risk mitigation of antibodies with fast clearance

(2012) Isidro Hötzel et al.   mAbs

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

(2012) Ben-Quan Shen et al.   NATURE BIOTECHNOLOGY

A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model

(2012) Takehisa Kitazawa et al.   NATURE MEDICINE

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treating Diabetes and Obesity with an FGF21-Mimetic Antibody Activating the  Klotho/FGFR1c Receptor Complex

(2012) I. N. Foltz et al.   Science Translational Medicine

Pharmacological modulation of GITRL/GITR system: therapeutic perspectives

(2011) Giuseppe Nocentini et al.   BRITISH JOURNAL OF PHARMACOLOGY

An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

(2011) Nicholas S. Wilson et al.   CANCER CELL

Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies

(2011) Jennifer Q. Dong et al.   CLINICAL PHARMACOKINETICS

Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences

(2011) W. Wang et al.   DRUG METABOLISM AND DISPOSITION

Development of high concentration protein biopharmaceuticals: The use of platform approaches in formulation development

(2011) Nicholas W. Warne   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Modulation of antibody effector function

(2011) John R. Desjarlais et al.   EXPERIMENTAL CELL RESEARCH

Interaction with Fc RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

(2011) A. L. White et al.   JOURNAL OF IMMUNOLOGY

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data

(2011) Rong Deng et al.   mAbs

Distinct Aggregation Mechanisms of Monoclonal Antibody Under Thermal and Freeze-Thaw Stresses Revealed by Hydrogen Exchange

(2011) Aming Zhang et al.   PHARMACEUTICAL RESEARCH

Complex Pharmacokinetics of a Humanized Antibody Against Human Amyloid Beta Peptide, Anti-Abeta Ab2, in Nonclinical Species

(2011) Yulia Vugmeyster et al.   PHARMACEUTICAL RESEARCH

The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors

(2011) Agnès Maillet et al.   PHARMACEUTICAL RESEARCH

Inhibitory Fc  Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies

(2011) F. Li et al.   SCIENCE

Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics

(2010) C. Andrew Boswell et al.   BIOCONJUGATE CHEMISTRY

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types

(2010) Paula J. Kaplan-Lefko et al.   CANCER BIOLOGY & THERAPY

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Ron J. Keizer et al.   CLINICAL PHARMACOKINETICS

Is There an Increased Risk of Lymphoma and Malignancies Under Anti- TNF Therapy in IBD?

(2010) P. Lakatos et al.   CURRENT DRUG TARGETS

Monoclonal Antibody-Glial-Derived Neurotrophic Factor Fusion Protein Penetrates the Blood-Brain Barrier in the Mouse

(2010) Q.-H. Zhou et al.   DRUG METABOLISM AND DISPOSITION

Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR

(2010) Takuo Suzuki et al.   JOURNAL OF IMMUNOLOGY

Potential aggregation prone regions in biotherapeutics

(2010) Xiaoling Wang et al.   mAbs

Single-Batch Production of Recombinant Human Polyclonal Antibodies

(2010) Lars S. Nielsen et al.   MOLECULAR BIOTECHNOLOGY

Re-Engineering Erythropoietin as an IgG Fusion Protein That Penetrates the Blood−Brain Barrier in the Mouse

(2010) Qing-Hui Zhou et al.   MOLECULAR PHARMACEUTICS

Enhanced antibody half-life improves in vivo activity

(2010) Jonathan Zalevsky et al.   NATURE BIOTECHNOLOGY

Development trends for human monoclonal antibody therapeutics

(2010) Aaron L. Nelson et al.   NATURE REVIEWS DRUG DISCOVERY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reduced elimination of IgG antibodies by engineering the variable region

(2010) T. Igawa et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease

(2009) Mohammad Tabrizi et al.   AAPS Journal

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

(2009) Siddhartha Jaiswal et al.   CELL

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

(2009) Karl S. Peggs et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates

(2009) Y. A. Yeung et al.   JOURNAL OF IMMUNOLOGY

A modeling analysis of the effects of molecular size and binding affinity on tumor targeting

(2009) M. M. Schmidt et al.   MOLECULAR CANCER THERAPEUTICS

Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis

(2009) K Vandenbroucke et al.   Mucosal Immunology

Engineering of stable bispecific antibodies targeting IL-17A and IL-23

(2009) Robert Mabry et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY